This article was originally published in The Gray Sheet
Executive SummaryAcquisition of development stage CardioGene Therapeutics gives the Natick, Massachusetts firm a foothold in the gene therapy market for cardiovascular diseases such as angiogenesis, restenosis and congestive heart failure. Boston Scientific the purchases all outstanding stock in the Princeton, New Jersey firm, which holds patent positions covering the "use of device technology for delivery of genetic material to sites within the vasculature and the myocardium"
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.